Epizyme (EPZM) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Epizyme (EPZM) PT Lowered to $19 at RBC Capital; Reiterates Outperform
March 9, 2017 1:20 PM ESTRBC Capital lowered its price target on Epizyme (NASDAQ: EPZM) to $19.00 (from $26.00) while maintaining a Outperform rating. Epizyme provided a development update and discussed its current understanding of tazemetostats mechanism of action .
Analyst Simos Simeonidis commented, "Epizyme provided a development update on... More
